 In its guidance on EUAs for vaccines, the FDA said earlier in October that a drugmaker should continue to collect data in any ongoing trials for as long as feasible, even after getting an authorization, and work toward submission of a formal approval application as soon as possible. Pfizer said it may have an ethical duty to inform at least some study volunteers that they have been given a placebo. 